MCRB
NASDAQ · Biotechnology
Seres Therapeutics Inc
$7.70
-0.02 (-0.26%)
Financial Highlights (FY 2026)
Revenue
850.7K
Net Income
6.14M
Gross Margin
—
Profit Margin
721.9%
Rev Growth
-71.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 56.5% | 56.5% |
| Operating Margin | -1,683.9% | -1,515.5% | 15.1% | 14.3% |
| Profit Margin | 721.9% | 685.8% | 11.6% | 9.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 850.7K | 3.00M | 47.44M | 44.02M |
| Gross Profit | — | — | 26.82M | 24.89M |
| Operating Income | -14,324,533 | -45,426,637 | 7.15M | 6.28M |
| Net Income | 6.14M | 19.47M | 5.52M | 4.21M |
| Gross Margin | — | — | 56.5% | 56.5% |
| Operating Margin | -1,683.9% | -1,515.5% | 15.1% | 14.3% |
| Profit Margin | 721.9% | 685.8% | 11.6% | 9.6% |
| Rev Growth | -71.6% | -71.6% | +12.6% | +20.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 29.85M | 36.89M |
| Total Equity | — | — | 62.46M | 70.73M |
| D/E Ratio | — | — | 0.48 | 0.52 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 8.19M | 27.42M | 8.75M | 8.39M |
| Free Cash Flow | — | — | 3.59M | 3.32M |